LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review

References

• World Health Organization [homepage on the Internet]Chronic Respiratory Diseases: Burden of COPDGenevaWorld Health Organization2017 Available from: http://www.who.int/respiratory/copd/burden/en/Accessed November 3, 2017
   Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease [homepage on the Internet]Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease [updated 2017]. Available from: www.goldcopd.org/Accessed December 2016
   Google Scholar
• CalzettaLMateraMGCazzolaMPharmacological interaction between LABAs and LAMAs in the airways: optimizing synergyEur J Pharmacol201576116817325981302
   PubMed Web of Science ®Google Scholar
• CazzolaMCalzettaLOraJPuxedduERoglianiPMateraMGSearching for the synergistic effect between aclidinium and formoterol: from bench to bedsideRespir Med2015109101305131126303336
   PubMed Web of Science ®Google Scholar
• RodrigoGJPriceDAnzuetoALABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysisInt J Chron Obstruct Pulmon Dis20171290792228360514
   PubMed Web of Science ®Google Scholar
• RoglianiPCalzettaLCoppolaAOptimizing drug delivery in COPD: the role of inhaler devicesRespir Med201712461428284323
   PubMed Web of Science ®Google Scholar
• MoherDLiberatiATetzlaffJAltmanDGPRISMA GroupPreferred reporting items for systematic reviews and meta-analyses: the PRISMA StatementOpen Med200933e123e13021603045
   PubMedGoogle Scholar
• MoherDShamseerLClarkeMPreferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statementSyst Rev20154125554246
   PubMed Web of Science ®Google Scholar
• CalzettaLRoglianiPMateraMGCazzolaMA systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPDChest201614951181119626923629
   PubMed Web of Science ®Google Scholar
• GuyattGOxmanADAklEAGRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tablesJ Clin Epidemiol201164438339421195583
   PubMed Web of Science ®Google Scholar
• D’UrzoARennardSKerwinEA randomised double-blind, placebo-controlled, long-term extension study of the efficacy, safety and tolerability of fixed-dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary diseaseRespir Med2017125394828340861
   PubMed Web of Science ®Google Scholar
• DonohueJFSoongWWuXShresthaPLeiALong-term safety of aclidinium bromide/formoterol fumarate fixed-dose combination: results of a randomized 1-year trial in patients with COPDRespir Med2016116414827296819
   PubMed Web of Science ®Google Scholar
• VogelmeierCPaggiaroPLDorcaJEfficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD studyEur Respir J20164841030103927492833
   PubMed Web of Science ®Google Scholar
• SinghDJonesPWBatemanEDEfficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised studyBMC Pulm Med20141417825404569
   PubMed Web of Science ®Google Scholar
• D’UrzoADRennardSIKerwinEMEfficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD studyRespir Res20141512325756831
   PubMed Web of Science ®Google Scholar
• MartinezFJRabeKFFergusonGTEfficacy and safety of glycopyrrolate/formoterol metered dose inhaler formulated using co-suspension delivery technology in patients with COPDChest2017151234035727916620
   PubMed Web of Science ®Google Scholar
• HananiaNATashkinDPKerwinEMLong-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with chronic obstructive pulmonary diseaseRespir Med201712610511528427541
   PubMed Web of Science ®Google Scholar
• VogelmeierCFGagaMAalamian-MattheisMEfficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trialRespir Res201718114028720132
   PubMed Web of Science ®Google Scholar
• FergusonGTTaylorAFThachCLong-term maintenance bronchodilation with indacaterol/glycopyrrolate versus indacaterol in moderate-to-severe COPD patients: the FLIGHT 3 StudyChronic Obstr Pulm Dis20163471672828848898
   PubMedGoogle Scholar
• WedzichaJABanerjiDChapmanKRIndacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPDN Engl J Med2016374232222223427181606
   PubMed Web of Science ®Google Scholar
• ZhongNWangCZhouXLANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPDInt J Chron Obstruct Pulmon Dis2015101015102626082625
   PubMed Web of Science ®Google Scholar
• MahlerDAKerwinEAyersRTFLIGHT: efficacy and safety of QVA149 (indacaterol/glycopyrrolate) versus its monocomponents and placebo in patients with COPDAm J Respir Crit Care Med201519291068107926177074
   PubMed Web of Science ®Google Scholar
• BeehKMKornSBeierJEffect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT studyRespir Med2014108458459224534204
   PubMed Web of Science ®Google Scholar
• BatemanEDFergusonGTBarnesNDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyEur Respir J20134261484149423722616
   PubMed Web of Science ®Google Scholar
• WedzichaJADecramerMFickerJHAnalysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group studyLancet Respir Med20131319920924429126
   PubMed Web of Science ®Google Scholar
• VogelmeierCFBatemanEDPallanteJEfficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group studyLancet Respir Med201311516024321804
   PubMed Web of Science ®Google Scholar
• FergusonGTKarpelJBennettNEffect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studiesNPJ Prim Care Respir Med2017271728154373
   PubMed Web of Science ®Google Scholar
• O’DonnellDECasaburiRFrithPEffects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPDEur Respir J2017494 pii:1601348
   Web of Science ®Google Scholar
• BuhlRMaltaisFAbrahamsRTiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4)Eur Respir J201545496997925573406
   PubMed Web of Science ®Google Scholar
• SinghDFergusonGTBolitschekJTiotropium + olodaterol shows clinically meaningful improvements in quality of lifeRespir Med2015109101312131926320402
   PubMed Web of Science ®Google Scholar
• KerwinEMKalbergCJGalkinDVUmeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week studyInt J Chron Obstruct Pulmon Dis20171274575528280319
   PubMed Web of Science ®Google Scholar
• SinghDWorsleySZhuCQHardakerLChurchAUmeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trialBMC Pulm Med2015159126286141
   PubMed Web of Science ®Google Scholar
• DonohueJFWorsleySZhuCQHardakerLChurchAImprovements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbationsRespir Med2015109787088126006754
   PubMed Web of Science ®Google Scholar
• DecramerMAnzuetoAKerwinEEfficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trialsLancet Respir Med20142647248624835833
   PubMed Web of Science ®Google Scholar
• Maleki-YazdiMRKaelinTRichardNZvarichMChurchAEfficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trialRespir Med2014108121752176025458157
   PubMed Web of Science ®Google Scholar
• MaltaisFSinghSDonaldACEffects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double-blind clinical trialsTher Adv Respir Dis20148616918125452426
   PubMed Web of Science ®Google Scholar
• DonohueJFMaleki-YazdiMRKilbrideSMehtaRKalbergCChurchAEfficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPDRespir Med2013107101538154623830094
   PubMed Web of Science ®Google Scholar
• ObaYSarvaSTDiasSEfficacy and safety of long-acting β-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysisThorax2016711152526490732
   PubMed Web of Science ®Google Scholar
• LahousseLVerhammeKMStrickerBHBrusselleGGCardiac effects of current treatments of chronic obstructive pulmonary diseaseLancet Respir Med20164214916426794033
   PubMed Web of Science ®Google Scholar
• SuissaSDell’AnielloSErnstPConcurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular eventsEur Respir J2017495 pii:1602245
   Web of Science ®Google Scholar
• CazzolaMCalzettaLRoglianiPMateraMGTiotropium formulations and safety: a network meta-analysisTher Adv Drug Saf201781173028203364
   PubMed Web of Science ®Google Scholar
• RoglianiPCalzettaLCoppolaAOptimizing drug delivery in COPD: the role of inhaler devicesRespir Med201712461428284323
   PubMed Web of Science ®Google Scholar
• CalzettaLRoglianiPOraJPuxedduECazzolaMMateraMGLABA/LAMA combination in COPD: a meta-analysis on the duration of treatmentEur Respir Rev201726143 pii:160043
   PubMed Web of Science ®Google Scholar
• PriceDØstremAThomasMWelteTDual bronchodilation in COPD: lung function and patient-reported outcomes – a reviewInt J Chron Obstruct Pulmon Dis20171214116828115839
   PubMed Web of Science ®Google Scholar
• HoritaNGotoAShibataYLong-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD)Cochrane Database Syst Rev20172CD01206628185242
   PubMed Web of Science ®Google Scholar
• DecramerMLChapmanKRDahlROnce-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group studyLancet Respir Med20131752453324461613
   PubMed Web of Science ®Google Scholar
• VogelmeierCHedererBGlaabTTiotropium versus salmeterol for the prevention of exacerbations of COPDN Engl J Med2011364121093110321428765
   PubMed Web of Science ®Google Scholar
• CalverleyPMAndersonJACelliBSalmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med2007356877578917314337
   PubMed Web of Science ®Google Scholar
• OfirDLavenezianaPWebbKALamYMO’DonnellDEMechanisms of dyspnea during cycle exercise in symptomatic patients with GOLD stage I chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2008177662262918006885
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease [homepage on the Internet]Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease [updated 2018]. Available from: www.goldcopd.org/Accessed December 2017
   Google Scholar
• WangMTLiouJTLinCWAssociation of cardiovascular risk with inhaled long-acting bronchodilators in patients with chronic obstructive pulmonary disease: a nested case-control studyJAMA Intern Med2018178222923829297057
   PubMed Web of Science ®Google Scholar
• PapiAVestboJFabbriLExtrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trialLancet2018391101251076108429429593
   PubMed Web of Science ®Google Scholar
• LipsonDABarnhartFBrealeyNOnce-daily single-inhaler triple versus dual therapy in patients with COPDN Engl J Med2018378181671168029668352
   PubMed Web of Science ®Google Scholar
• ChapmanKRHurstJRFrentSMLong-term triple therapy deescalation to indacaterol/glycopyrronium in COPD patients (SUNSET): a randomized, double-blind, triple-dummy clinical trialAm J Respir Crit Care Med2018198332933929779416
   PubMed Web of Science ®Google Scholar
• CazzolaMPageCPRoglianiPMateraMGβ2-agonist therapy in lung diseaseAm J Respir Crit Care Med2013187769069623348973
   PubMed Web of Science ®Google Scholar
• SlackRJBarrettVJMorrisonVSIn vitro pharmacological char-acterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of actionJ Pharmacol Exp Ther2013344121823023131596
   PubMed Web of Science ®Google Scholar
• BattramCCharltonSJCuenoudBIn vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of actionJ Pharmacol Exp Ther2006317276277016434564
   PubMed Web of Science ®Google Scholar
• ApariciMGómez-AngelatsMVilellaDPharmacological char-acterization of abediterol, a novel inhaled β(2)-adrenoceptor agonist with long duration of action and a favorable safety profile in preclinical modelsJ Pharmacol Exp Ther2012342249750922588259
   PubMed Web of Science ®Google Scholar
• BouyssouTCasarosaPNalineEPharmacological characterization of olodaterol, a novel inhaled beta2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical modelsJ Pharmacol Exp Ther20103341536220371707
   PubMed Web of Science ®Google Scholar
• NalineETrifilieffAFairhurstRAAdvenierCMolimardMEffect of indacaterol, a novel long-acting beta2-agonist, on isolated human bronchiEur Respir J200729357558117135231
   PubMed Web of Science ®Google Scholar
• CalzettaLMateraMGCazzolaMPharmacological mechanisms leading to synergy in fixed-dose dual bronchodilator therapyCurr Opin Pharmacol2018409510329626716
   PubMed Web of Science ®Google Scholar
• CasarosaPBouyssouTGermeyerSSchnappAGantnerFPieperMPreclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugsJ Pharmacol Exp Ther2009330266066819478135
   PubMed Web of Science ®Google Scholar
• CazzolaMBeehKMPriceDRocheNAssessing the clinical value of fast onset and sustained duration of action of long-acting bronchodilators for COPDPulm Pharmacol Ther201531687825727846
   PubMed Web of Science ®Google Scholar
• RoglianiPCalzettaLOraJPharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchiEur J Pharmacol201576138339025952728
   PubMed Web of Science ®Google Scholar
• NalineEGrassin DelyleSSalvatorHComparison of the in vitro pharmacological profiles of long-acting muscarinic antagonists in human bronchusPulm Pharmacol Ther201849465329337266
   PubMed Web of Science ®Google Scholar
• GavaldàARamosICarcasonaCThe in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromidePulm Pharmacol Ther201428211412124928173
   PubMed Web of Science ®Google Scholar
• VillettiGPastoreFBergamaschiMBronchodilator activity of (3R)-3-[[[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino] carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyclo[2.2.2] octane bromide (CHF5407), a potent, long-acting, and selective muscarinic M3 receptor antagonistJ Pharmacol Exp Ther2010335362263520805306
   PubMed Web of Science ®Google Scholar
• SalmonMLuttmannMAFoleyJJPharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseasesJ Pharmacol Exp Ther2013345226027023435542
   PubMed Web of Science ®Google Scholar
• StaresinicAGSorknessCAFluticasone propionate: a potent inhaled corticosteroid for the treatment of asthmaExpert Opin Pharmacother2000161227124411249490
   PubMedGoogle Scholar
• Daley-YatesPTParkinsDAThomasMJGillettBHouseKWOrtegaHGPharmacokinetic, pharmacodynamic, efficacy, and safety data from two randomized, double-blind studies in patients with asthma and an in vitro study comparing two dry-powder inhalers delivering a combination of salmeterol 50 microg and fluticasone propionate 250 microg: implications for establishing bioequivalence of inhaled productsClin Ther200931237038519302910
   PubMed Web of Science ®Google Scholar